Nebicapone

Last updated
Nebicapone
Nebicapone.svg
Clinical data
Other namesBIA 3-202; 3-Nitro-5-phenylacetyl catechol
Drug class Catechol O-methyltransferase inhibitor
Identifiers
  • 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H11NO5
Molar mass 273.244 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
  • InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
  • Key:MRFOLGFFTUGAEB-UHFFFAOYSA-N

Nebicapone (developmental code name BIA 3-202) is a catechol O-methyltransferase (COMT) inhibitor which was under development for the treatment of Parkinson's disease but was never marketed. [1] [2] It is a nitrocatechol and is structurally related to entacapone, nitecapone, and tolcapone. [2] The drug shows peripheral selectivity and does not significantly act in the brain. [2] In contrast to the centrally penetrant tolcapone, nebicapone does not potentiate the psychostimulant-like effects of amphetamine in animals. [3] [4] Nebicapone was found to be effective for Parkinson's disease in clinical trials. [5] However, it also showed hepatotoxicity, including elevated liver enzymes. [2] [5] [6] As a result, its development was discontinued by 2014. [6] Nebicapone was first described in the scientific literature by 2000. [7] [8]

See also

References

  1. ↑ "Nebicapone: Uses, Interactions, Mechanism of Action". DrugBank Online. 20 May 2019. Retrieved 8 October 2024.
  2. 1 2 3 4 Haasio K (2010). "Toxicology and safety of COMT inhibitors". Int Rev Neurobiol. International Review of Neurobiology. 95: 163–189. doi:10.1016/B978-0-12-381326-8.00007-7. ISBN   978-0-12-381326-8. PMID   21095462.
  3. ↑ Guay DR (January 1999). "Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease". Pharmacotherapy. 19 (1): 6–20. doi:10.1592/phco.19.1.6.30516. PMID   9917075. It also enhances locomotor hyperactivity induced by amphetamine and nomifensine and stereotypy induced by amphetamine, and stimulates exploratory activity in the open field test in rats and mice.14 Tolcapone potentiates levodopa antagonism of haloperidol-induced catalepsy in MPP+-lesioned mice (murine model of Parkinson's disease) and potentiates and prolongs levodopa-induced circling behavior in rats with 6-hydroxydopamine-induced nigrostriatal pathway lesions (another animal model of Parkinson's disease).23, 24 [...] The effect of tolcapone on animal models of depression was evaluated in two studies. In rats with chronic mild stress-induced anhedonia, tolcapone 10 or 30 mg/kg twice/day by intraperitoneal injection prevented the stress-induced anhedonic state compared with vehicle-treated controls.28 Another rat study using the forced swimming test and learned helplessness paradigm, found no significant antidepressant activity of the agent.29 The relevance of these findings to the management of depression in humans with both parkinsonian and nonparkinsonian disease is unknown.
  4. ↑ Parada A, Soares-da-Silva P (October 2000). "POSTER COMMUNICATIONS: 49P. BIA 3-202 does not potentiate locomotor hyperactivity during increased dopaminergic stimulation". British Journal of Pharmacology. 131 (Suppl). Wiley: 38P–129P. PMC   1910551 . Tolcapone administered 6 h before amphetamine challenge was found to significantly increase locomotor activity in rats treated with 0.5 and 2.0 mg kg-1 amphetamine. In rats given 4.0 mg kg-1 amphetamine, tolcapone produced a marked decrease in locomotor activity and increased two-fold the duration of the stereotyped behaviour.
  5. 1 2 Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M (2012). "A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice". Clin Neuropharmacol. 35 (4): 185–190. doi:10.1097/WNF.0b013e31825c034a. PMID   22805229.
  6. 1 2 Kiss LE, Soares-da-Silva P (November 2014). "Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility". J Med Chem. 57 (21): 8692–8717. doi:10.1021/jm500572b. PMID   25080080.
  7. ↑ Vieira-Coelho, M. A., Borges, N., Parada, A., Learmonth, D. A., Benes, J., & Soares-da-Silva, P. (2000). ORAL COMMUNICATIONS-BIA 3-202, a long-acting catechol-O-methyltransferase inhibitor with limited brain access. British Journal of Pharmacology-Proceedings Supplement, 2-2. https://scholar.google.com/scholar?cluster=3859334956887569813
  8. ↑ Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, Soares-da-Silva P (May 2001). "BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation". Eur J Pharmacol. 420 (1): 27–32. doi:10.1016/s0014-2999(01)01020-2. PMID   11412836.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.